Open AccessImmune checkpoint inhibitors are superior to docetaxel as second‐line therapy for patients with non‐small cell lung carcinoma
Author(s) -
Fillon Mike
Publication year - 2018
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21423
Subject(s) - docetaxel , medicine , oncology , second line , lung cancer , carcinoma , immune checkpoint , immunotherapy , chemotherapy , first line , cancer
Key Points When compared with docetaxel, checkpoint inhibitors prolong overall survival in second‐line and later lines of treatment among patients with advanced NSCLC. There was no significant increase in survival noted for patients with EGFR‐ mutant tumors. Checkpoint inhibitors should be considered for these patients only after all other effective therapies have been tried. Smoking status appears to have minimal effect on the relative efficacy of these 2 therapies.